Hosted on MSN2mon
FDA clears Amylyx to resume ALS drug trial in North AmericaIt aims to evaluate the safety and biological activity of AMX0114, which targets calpain-2, a protein linked to neurodegenerative processes. Approximately 48 individuals with ALS will be involved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback